TrovaGene (TROV) has risen sharply, recording gains of 9.13% in the past 4 weeks. However, the stock has corrected -1.96% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.71% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
TrovaGene, Inc. is up 11.56% in the last 3-month period. Year-to-Date the stock performance stands at 1.85%. The stock has recorded a 20-day Moving Average of 0.15% and the 50-Day Moving Average is 9.77%.
TrovaGene (NASDAQ:TROV): The stock opened at $5.62 on Friday but the bulls could not build on the opening and the stock topped out at $5.68 for the day. The stock traded down to $5.48 during the day, due to lack of any buying support eventually closed down at $5.50 with a loss of -2.48% for the day. The stock had closed at $5.64 on the previous day. The total traded volume was 195,718 shares.
Also, In a research note released to the investors, Cantor Fitzgerald upgrades its rating on TrovaGene (NASDAQ:TROV).The analysts at the brokerage house have a current rating of Buy on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The rating by the firm was issued on August 8, 2016.
Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Companys primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).